# Evaluation of NWRD08 for HPV-16 and/or HPV-18 Related Cervical HSIL

> **NCT07175662** · PHASE2 · RECRUITING · sponsor: **Newish Biotech (Wuxi) Co., Ltd.** · enrollment: 150 (estimated)

## Conditions studied

- High-grade Squamous Intraepithelial Lesion (HSIL)

## Interventions

- **BIOLOGICAL:** NWRD08 administered by electroporation
- **BIOLOGICAL:** Placebo administered by electroporation

## Key facts

- **NCT ID:** NCT07175662
- **Lead sponsor:** Newish Biotech (Wuxi) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-11
- **Primary completion:** 2027-05-30
- **Final completion:** 2027-08-30
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2026-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07175662

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07175662, "Evaluation of NWRD08 for HPV-16 and/or HPV-18 Related Cervical HSIL". Retrieved via AI Analytics 2026-06-11 from https://api.ai-analytics.org/clinical/NCT07175662. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*